Nuvation Bio Inc
NUVB4.980USD
+0.340+7.33%
Fechamento 11/11, 16:00（ET）Cotações atrasadas em 15 min
1.71BValor de mercado
PerdaP/L TTM
Mais detalhes de Nuvation Bio Inc Empresa
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Informações de Nuvation Bio Inc
Código da empresaNUVB
Nome da EmpresaNuvation Bio Inc
Data de listagemJul 01, 2020
CEODr. David T. Hung, M.D.
Número de funcionários220
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 01
Endereço357 Tehama Street, Floor 3
CidadeSAN FRANCISCO
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal94103
Telefone14157543517
Sitehttps://www.nuvationbio.com/
Código da empresaNUVB
Data de listagemJul 01, 2020
CEODr. David T. Hung, M.D.
Executivos da empresa Nuvation Bio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Hung (David T)
17.58%
Fidelity Management & Research Company LLC
14.72%
Decheng Capital LLC
7.57%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
4.49%
Outro
49.51%
Investidores
Investidores
Proporção
Hung (David T)
17.58%
Fidelity Management & Research Company LLC
14.72%
Decheng Capital LLC
7.57%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
4.49%
Outro
49.51%
Tipos de investidores
Investidores
Proporção
Investment Advisor
30.16%
Individual Investor
19.16%
Hedge Fund
12.75%
Venture Capital
11.20%
Investment Advisor/Hedge Fund
10.94%
Research Firm
1.02%
Bank and Trust
0.23%
Pension Fund
0.16%
Family Office
0.03%
Outro
14.35%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
355
228.75M
66.72%
-24.74M
2025Q2
346
279.19M
82.03%
-27.71M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Hung (David T)
60.28M
17.61%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.47M
14.75%
+440.09K
+0.88%
Jun 30, 2025
Decheng Capital LLC
25.95M
7.58%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
20.99M
6.13%
+5.12M
+32.27%
Jun 30, 2025
The Vanguard Group, Inc.
15.84M
4.63%
+505.23K
+3.29%
Jun 30, 2025
Omega Fund Management, LLC
11.04M
3.23%
-2.03M
-15.53%
Jun 30, 2025
Laurion Capital Management LP
10.24M
2.99%
+369.63K
+3.74%
Jun 30, 2025
Octagon Capital Advisors LP
7.69M
2.25%
-208.67K
-2.64%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.99M
1.75%
+864.19K
+16.84%
Jun 30, 2025
State Street Investment Management (US)
5.56M
1.62%
+702.97K
+14.48%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
1.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.48%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.23%
Tema Oncology ETF
1.17%
ALPS Medical Breakthroughs ETF
0.75%
iShares U.S. Pharmaceuticals ETF
0.33%
iShares Micro-Cap ETF
0.18%
iShares Health Innovation Active ETF
0.13%
Avantis US Small Cap Equity ETF
0.11%
iShares Biotechnology ETF
0.08%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção1.64%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.48%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.23%
Tema Oncology ETF
Proporção1.17%
ALPS Medical Breakthroughs ETF
Proporção0.75%
iShares U.S. Pharmaceuticals ETF
Proporção0.33%
iShares Micro-Cap ETF
Proporção0.18%
iShares Health Innovation Active ETF
Proporção0.13%
Avantis US Small Cap Equity ETF
Proporção0.11%
iShares Biotechnology ETF
Proporção0.08%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
